Skip to content
Business Times – Lifestyle
Author:
Elixiron Immunotherapeutics
Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer’s Disease
June 10, 2026